Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.65M
Average 0.39M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
AbCellera Biologics Inc. NASDAQ:ABCL | $3.75B | $11.49 | Not rated | -11.4 | +207.04% |
Xeris Biopharma Holdings, Inc. NASDAQ:XERS | $3.04B | $16.66 | Undervalued | 98.7 | +142.98% |
Celldex Therapeutics, Inc. NASDAQ:CLDX | $2.26B | $28.83 | Not rated | -7.8 | +11.53% |
Immunome, Inc. NASDAQ:IMNM | $2.22B | $18.77 | Not rated | -9.1 | -5.14% |
Biohaven Ltd. NYSE:BHVN | $2.09B | $13.82 | Not rated | -3.1 | +41.74% |
Vera Therapeutics, Inc. NASDAQ:VERA | $2.03B | $28.10 | Not rated | -6.8 | -4.02% |
Maze Therapeutics, Inc. NASDAQ:MAZE | $1.88B | $34.33 | Not rated | -11.0 | -8.83% |
Zymeworks Inc. NASDAQ:ZYME | $1.83B | $26.24 | Not rated | -16.6 | +12.76% |
Ardelyx, Inc. NASDAQ:ARDX | $776.74M | $3.09 | Not rated | -24.5 | -44.86% |
Janux Therapeutics, Inc. NASDAQ:JANX | $695.66M | $11.37 | Not rated | -7.6 | -64.01% |
Continue the stock analysis
Jump to another research area for this company.